Wockhardt gets FDA approval for Ceftriaxone injection

By Elaine Rigoli

Tampa, Fla., May 15 - Wockhardt Ltd. has received approval from the Food and Drug Administration to market Ceftriaxone sodium injection.

The company's U.S. subsidiary, Wockhardt USA, Inc., is expected to launch the cephalosporin antibiotic in the next few weeks, according to a news release.

Ceftriaxone sodium is the generic version of Hoffman La Roche's Rocephin injection, the release said.

With Ceftriaxone, the company now has 12 products in the U.S. market, compared to five last year. The company has more than 20 products awaiting FDA approval.

Wockhardt is a technology-driven pharmaceutical and biotechnology company located in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.